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Abstract 
Bone marrow mesenchymal stem/stromal cells (MSCs) maintain bone homeostasis and repair through 
the ability to expand in response to mitotic stimuli and differentiate into skeletal lineages. Signalling 
mechanisms that enable precise control of MSC function remain unclear. Here we report that by 
initially examining differences in signalling pathway expression profiles of individual MSC clones, 
we identified a previously unrecognised signalling mechanism regulated by epidermal growth factor 
(EGF) in primary human MSCs.  We demonstrate that EGF is able to activate E-catenin, a key 
component of the canonical Wnt signalling pathway. EGF is able to induce nuclear translocation of E-
catenin in human MSCs but does not drive expression of Wnt target genes or T cell factor (TCF) 
activity in MSC reporter cell lines. Using an efficient Design of Experiments (DoE) statistical 
analysis, with different combinations and concentrations of EGF and Wnt ligands, we were able to 
confirm that EGF does not influence the Wnt/E-catenin pathway in MSCs. We show that the effects of 
EGF on MSCs are temporally regulated to initiate early ³classical´  EGF signalling mechanisms (e.g 
via mitogen activated protein kinase) with delayed activation of E-catenin. By RNA-sequencing, we 
identified gene sets that were exclusively regulated by the EGF/E-catenin pathway, which were 
distinct from classical EGF-regulated genes. However, subsets of classical EGF gene targets were 
significantly influenced by EGF/E-catenin activation. These signalling pathways cooperate to enable 
EGF-mediated proliferation of MSCs by alleviating the suppression of cell cycle pathways induced by 
classical EGF signalling. 
 
Key words: 
EpidHUPDO JURZWKIDFWRUȕ-catenin, mesenchymal stem cells, integrin-linked kinase 
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Introduction 
Mesenchymal stem/stromal cells (MSCs, also referred to as bone marrow stromal cells or 
mesenchymal stem cells) are a major stromal component of bone marrow. Related cell types are 
present in many other tissues, where they often act to support parenchymal cell function [1, 2]. MSCs 
have the capacity to form fibroblastic colony-forming units (CFU-f), due to the presence of a 
progenitor cell population and are able to differentiate into osteoblasts, chondrocytes and adipocytes 
[3], however MSC cultures are heterogeneous with no single selective and widely adopted MSC 
surface marker [4, 5]. Despite intensive efforts, there is still a distinct lack of understanding of the 
specific mechanisms regulating MSC proliferation and differentiation, which may in part be due to the 
heterogeneity of the MSC pool. In our own studies of immortalised clonal MSC lines [6], we found 
significant variations in potency, cell morphology and global expression profiles with particularly 
striking differences in genes involved in Wnt, receptor tyrosine kinase (RTK) growth factor signalling 
and integrin-linked kinase (ILK)-regulated pathways. These signalling cascades have wide-ranging 
effects on development and tissue homeostasis through the regulation of essential cellular processes 
including survival, proliferation, migration, stem cell maintenance and differentiation.  
Canonical Wnt signalling involves the regulatory complex composed of adenomatous polyposis coli 
(APC)/Axin/GSK-ȕ [7]. In the presence of Wnt ligands bound to Frizzled receptors and LRP5/6 co-
receptors, the intracellular protein Dishevelled becomes activated and displaces GSK-ȕIURPWKH
APC/Axin complex, suppressing GSK-ȕ-PHGLDWHGSKRVSKRU\ODWLRQ RIȕ-catenin, thereby preventing 
its ubiquitination and proteasomal degradation. This results in the nuclear translocation of 
dephosphorylated DFWLYHȕ-catenin and recruitment of T cell factor/lymphoid enhancer factor 
(TCF/LEF) binding factors as co-activators for activation of gene transcription [8, 9]. :QWȕ-catenin 
signalling is associated with the regulation of bone mass. A reduction in canonical Wnt signalling is 
associated with low bone mineral density in patients with osteoporosis pseudoglioma syndrome that 
exhibit a loss of function mutation in LRP5 [10] and increased bone is observed in activating LRP5 
mutations [11]. Wnt signalling is also important in the control of MSC function and osteogenic 
induction, though with variable interpretations [11-16]. 
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$OWKRXJK *6.ȕDQGȕ-catenin are key components of the canonical Wnt signalling cascade, their 
biological functions are not exclusive to this pathway, and they act as points of crosstalk between 
:QWȕ-catenin and other key cellular signalling mechanisms. For example, integrin-linked kinase 
(ILK) is a serine/threonine kinase and downstream effector of integrin and growth factor signalling 
[17] WKDWHQKDQFHVȕ-catenin signalling through the phosphorylation and inactivation oI*6.ȕ[18, 
19]. RTK signalling pathways, including epidermal growth factor (EGF), platelet-derived growth 
factor (PDGF) and fibroblast growth factor (FGF), can also influence ȕ-catenin function. PDGF 
treatment is able to drive QXFOHDUWUDQVORFDWLRQ RIȕ-catenin by interfering with its interaction with 
$[LQDQG*6.ȕDQGWKHVXEVHTXHQWLQKLELWLRQ RIȕ-catenin phosphorylation [20]. EGF-induced 
LRP6 phosphorylation by the extracellular-signal-regulated kinase/mitogen activated protein kinase 
(ERK/MAPK) pathway has been shown to activate ȕ-catenin signalling [21, 22] and FGF signalling 
through MAPK can stimulatHERQHIRUPDWLRQ E\SUHYHQWLQJȕ-catenin degradation, mediated by the 
recruitment of a deubiquitinating enzyme [23]. EGF also has widespread effects on bone and cartilage 
development [24-27] and can influence the proliferation and differentiation of MSCs [28-32], though 
sometimes with apparently conflicting data. This may be related to specific effects of EGF on MSC 
proliferation versus differentiation and/or an incomplete understanding of interconnected downstream 
signal transduction pathways as the vast majority of studies consider EGF- DQGȕ-catenin-mediated 
signalling independently (Fig. 1A). Here we demonstrate for the first time WKDWȕ-catenin can be 
activated via a Wnt ligand-independent mechanism in human MSCs, through EGF, which runs 
parallel to, but is dLVWLQFW IURPWKHFDQRQLFDO:QWȕ-catenin pathway.  The EG)ȕ-catenin and 
classical EGF signalling pathways regulate discrete gene sets that act in concert to control EGF-
mediated proliferation of MSCs. 
 
Methods 
Cell culture 
In this study, we used human clonal MSC lines, immortalised with human telomerase reverse 
transcriptase (hTERT-MSCs) and primary human MSC cultures. hTERT-MSCs were used initially as 
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differences in EGF-mediated signalling were first identified in comparative analyses of the different 
MSC lines. Primary MSCs from different donors were used to ensure data were not an artefact of the 
immortalisation process, donor ID codes are provided in the figure legends. Bone samples were 
obtained with written informed consent from Clifton Park NHS Treatment Centre, under approval of 
the Local Research Ethics Committee. MSCs were extracted from bone samples as previously 
described [13]06&VZHUHPDLQWDLQHGLQ'XOEHFFR¶V0RGLILHG (DJOH¶V0HGLXP'0(0,QYLWURJHQ
containing 1% penicillin/streptomycin (P/S, Invitrogen) and 15% foetal bovine serum (FBS, Biosera), 
referred to as MSC basal medium. In all experiments, MSCs were used up to passage 5. hTERT-
MSCs were previously generated in the laboratory [6] and maintained in DMEM as described above 
but with 10% FBS, as were human dermal fibroblasts (HDFs, Fisher Scientific, Cat. No.10407693). 
 
Western Blot analysis 
Cell cultures were lysed in RIPA buffer (Thermo Scientific) containing 0.5% Protease Inhibitor III 
(Merck) and 1mM Sodium Orthovanadate (Sigma). Samples were electrophoresed and then 
transferred to a PVDF membrane. Membranes were probed with primary antibodies overnight at 4ºC, 
followed by HRP-conjugated secondary antibodies. Antibody information is provided in the 
Supplemental Material. Protein was visualised using enhanced chemiluminescence reagents (ECL, 
*(+HDOWKFDUHDFFRUGLQJWRPDQXIDFWXUHU¶VLQVWUXFWLRQVDQGTXDQWLILFDWLRQ ZDVSHUIRUPHGXVLQJ
Image J. For western blot analysis following treatment with type I collagen, tissue culture plastic was 
coated with type I collagen (Sigma, 3, 6 and 10mg/ml) and then pre-incubated in MSC basal medium 
overnight. Cells were seeded at a density of 2.1x104 per cm2 and incubated for 18 hours before 
analysis by Western Blotting.   
 
Inhibitor studies 
Cells were seeded at a density of 2.1x104 cells per cm2 in the appropriate basal medium for all 
inhibitor studies described in this section, experiments began following overnight adherence. hTERT-
MSCs were treated with an ILK inhibitor, ILKi (Cpd-22; 0.6, 1, 2.5µM; Merck), EGFR inhibitor, 
EGFRi (PD153035; 0.6, 1, 1.4µM; Santa Cruz) or PDGFR inhibitor, PDGFRi (sc-222142; 0.3, 0.5, 
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0.8µM; Santa Cruz) for 24 hours. Primary MSCs and HDFs were incubated in DMEM supplemented 
with 1% P/S and 0.5% FBS (synchronisation medium) for 24 hours, before a further incubation (15 
minutes or 6 hours) with recombinant EGF protein (1-100nM, Cell Guidance Systems). For RGD 
studies, primary MSCs were incubated in synchronisation medium for 24 hours. Samples were 
incubated overnight with 1µM ILKi or vehicle control after which RGD integrin binding peptide 
(100µg/ml, Anaspec) was added to samples for 6 hours. For growth factor plus ILKi studies, primary 
MSCs were incubated overnight with 1µM ILKi or vehicle control before a further incubation period 
of 24 hours untreated, or treated with 1µM ILKi, 10nM recombinant EGF, PDGF (20nM, Cell 
Guidance Systems) alone or in combination. 
 
MTT Assays of Viable Cell Number 
Cells were seeded at a density of 3.6x103 per cm2 and left overnight to adhere. hTERT-MSCs were 
WKHQLQFXEDWHGZLWKHLWKHUYHKLFOH FRQWUROȂP(*)5Lor ȝ03'*)5LDORQHRULQFRPELQDWLRQ
for a period of 24 or 72 hours. Primary MSCs were incubated overnight with 1µM ILKi or vehicle 
control treated before the addition of 10nM EGF for 24 or 48 hours. For samples exposed to the AP-1 
inhibitor, treatment began after overnight adherence. Samples were treated with 10nM EGF alone or 
in combination with the AP-1 inhibitor (17 ± 68nM, Biotechne, Cat. No. 2476) and were incubated for 
up to 120 hours. Similarly, primary MSCs were treated with the Wnt pathway inhibitor (5 or 10µM 
IWR-1, Sigma, Cat. No. I0161) with or without 10nM EGF. 5mg/ml MTT reagent was then added to 
the above samples and incubated at 370C for 3 hours. Cells were lysed in 0.1M acidic HCl in absolute 
isopropanol before absorbance was read at 570nm.  
 
Flow Cytometry 
MSCs were detached from tissue culture plastic with wash buffer (0.2% BSA and 5mM EDTA in 1X 
PBS), before incubation with primary DQWLERGLHV 3'*)5Įȝg/ml per 1 x 106 cells, Santa Cruz,) 
and EGFR (1ȝg/ml per 1 x 106
 
cells, Abcam). Samples were then incubated with FITC conjugated 
secondary antibodies (Thermo Fisher Scientific) followed by incubation with DAPI. Flow cytometric 
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analysis was performed using a CyAn ADP flow cytometer and analysed using Summit software 
(v4.3, Beckman Coulter). 
 
Immunofluorescence 
Primary MSCs were seeded at 2 x 104 cells per cm2
 
onto glass coverslips and left to adhere overnight. 
Cells were treated with varying concentrations of EGF (1nM, 10nM and 100nM) and left for 24 
hours. Samples were fixed for 15 minutes in 4% paraformaldehyde before incubation with anti-active 
ȕ-catenin (1:200, Merck) for 1 hour at room temperature. Secondary antibody (Alexor Fluor 647, 
Invitrogen) was added for a further hour in the dark at room temperature. Samples were 
counterstained with DAPI, and mounted using Prolong Gold Antifade mountant before visualisation 
using the LSM710 confocal microscopy system.  
 
Quantitative real time polymerase chain reaction (QPCR) 
Cell cultures were lysed in 0.5ml Trizol (Life Technologies) for 5 minutes, and frozen at -800C.  RNA 
was then extracted by chloroform phase separation and purification. cDNA was synthesised from 1µg 
RNA. QPCR was performed on the Applied Biosystems 7300 Real Time PCR System using SYBR 
Green PCR Master Mix. Primer sequences are given in the Supplemental Material. Fold changes are 
shown as 2(- , normalised to expression of RPS27a and relative to expression in untreated controls.  
 
TCF reporter assays 
Y201 hTERT-MSCs were lentivirally transduced with a TCF-EGFP reporter (Qiagen) to generate a 
stable MSC-Wnt-EGFP reporter line as previously described [33], and treated with recombinant EGF 
or Wnt3a. After 24 hours of treatment, cells were visualised by fluorescence microscopy or harvested 
in wash buffer for flow cytometric analysis (see above). The mouse mesenchymal cell line, C3H10T1/2, 
was transfected with a TCF reporter of Wnt signalling activity (TOPFlash). C3H10T1/2 cells were 
seeded at a density of 3.1 x 104 cells/cm2 and co-transfected with 0.03µg M50 (reporter) or M51 
(negative control) Super 8xTOPFlash and 0.003µg phRL-CMV (Renilla reporter, transfection control) 
using Lipofectamine/Plus Reagent (Invitrogen).  After 24 hours, cells were treated with 20 mM LiCl, 
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20mM NaCl, 200ng/ml Wnt3a (Biotechne) or 10nM EGF recombinant proteins for 24 hours. 
Luciferase activity was measured using a Dual Luciferase Reporter Assay Kit (Promega) using a 
Dynex illuminometer.  
 
Design of Experiments (DoE)-based analysis of combined EGF/Wnt effects 
The DoE was designed using Minitab software, using low, medium and high values of 0, 50 and 
100nM for EGF and 0, 300 and 600ng/ml for Wnt3a. Y201 hTERT-MSC-EGFP reporter cells were 
plated in a 96-well plate (3.1 x 104 cells/ cm2) and left to adhere for 24 hours. The medium was then 
replaced with growth factor containing medium in a randomised order. After 48 hours, cells were 
lysed in 0.1% Triton X-100 and read in a fluorimeter (excitation 485 nm; emission 520 nm). Data 
were analysed using Minitab using the response surface method.  
 
Edu Assay of Cell Proliferation 
Primary MSCs were seeded at a density of 1 x 104 cells/cm2
 
onto glass coverslips and allowed to 
adhere overnight in MSC basal medium. Following this, cells were incubated overnight in 
synchronisation medium. Cells were then exposed to 10nM EGF alone or in combination with 10µM 
IWR-1, or 200ng/ml Wnt3a plus 10µM EdU substrate.  After 48 hours EdU detection was performed 
DFFRUGLQJWRWKHPDQXIDFWXUHU¶VLQVWUXFWLRQV &OLFN-iT® EdU Imaging Kit, Invitrogen). Cells were 
counterstained with DAPI before mounting with Prolong Gold Antifade Mountant. Samples were 
visualised using the LSM710 confocal microscopy system and images were quantified using Image J.  
 
RNA-Seq analysis  
200,000 primary human MSCs at p4 were plated into two wells of three 6 well plates in triplicate. 
Cells were allowed to adhere overnight in MSC basal medium before stimulation for 24hrs with MSC 
basal medium (control), 10 nM EGF alone, or in combination with 10 µM IWR-1. Equivalent 
volumes of carrier, dH2O for EGF and DMSO for IWR-1, were added where relevant. After 24hrs, 
WRWDOFHOOXODU51$ZDVH[WUDFWHGIROORZLQJ WKHPDQXIDFWXUHU¶VJXLGHOLQHV XVLQJD1XFOHRVSLQ 51$,,
kit (Macherey-Nagel). Cells from two wells were pooled to increase yield. RNA quality was 
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examined using an Agilent bioanalyser. 1µg of good quality total RNA was used for mRNA 
sequencing library preparation using the NEBNext RNA Ultra Directional Library preparation kit for 
Illumina in conjunction with the NEBNext Poly(A) mRNA Magnetic Isolation Module (New England 
%LR/DEV,QFDQG1(%1H[WVLQJOHESLQGH[LQJ SULPHUVDFFRUGLQJWRWKHPDQXIDFWXUHU¶V
instructions. Libraries were pooled at equimolar ratios, and the pool was sent for 2 x 150 base paired 
end sequencing on a HiSeq 3000 at the University of Leeds Next Generation Sequencing Facility. 
 
Bioinformatics and identification of EGF gene targets 
Sequence reads were trimmed to remove any adapter sequences using Cutadapt version 1.8.3 [34]. 
Trimmed reads were aligned to version GRCh38 of the human genome using HISAT2 [35]. 
Transcriptomes were assembled and gene expression quantified using the Tuxedo pipeline (version 
2.2.1 ) [36]. Transcriptome assembly, merging, quantification and normalisation to fragments per 
kilobase per million mapped reads (FPKM) were performed using Cufflinks, Cuffmerge, Cuffquant 
and Cuffnorm, respectively. An analysis of variance model with experimental condition (Control, 
EGF, EGF+IWR-1) as factor was fit to the FPKM values in the R stats package [37], followed by 
Tukey HSD test to calculate adjusted p-values to estimate which groups differed. Target genes for 
gene set enrichment analysis (GSEA) were identified as either having p<0.05 in [Control versus EGF] 
and [Control versus EGF+IWR-1], but not [EGF versus EGF+IWR-1] (classical gene targets, gene set 
1), or by having p<0.05 in [Control versus EGF] and [EGF versus EGF+IWR-1], but not [Control 
versus EGF+I] (EGF/E-catenin gene targets, gene set 2). GSEA was performed using the Molecular 
Signature Database (MSigDB) web tool (http://software.broadinstitute.org/gsea) [38] and run against 
WKH³+DOOPDUNV´DQG³*HQH2QWRORJ\ %LRORJLFDO 3URFHVVHV´WRSURGXFHOLVWVRIJHQHVHWVDVVRFLDWHG
with those genes. 
 
Statistical analysis 
Details of the statistical analyses performed throughout this work can be found in the Supplemental 
Material. 
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Results 
57.,/.DQGȕ-catenin signalling are interrelated in human MSCs 
Interest in (*)ȕ-catenin signalling cross-talk was first stimulated by global gene expression analyses 
of four immortalised human clonal MSC lines (hTERT-MSCs; identified as Y101, Y201, Y102 and 
Y202) that showed distinct functional differences [6]. Several significantly differentially expressed 
pathways across the four MSC lines, including EGF/RTK, integrin, Wnt and ILK signalling were 
identified [6]3DWKZD\DQDO\VLVRIWKHJHQHH[SUHVVLRQSURILOHVUHYHDOHGDKLJKO\ HQULFKHG³IRFDO
DGKHVLRQ´QHWZRUNZLWKPDQ\GLIIHUHQWLDOO\ H[SUHVVHGJHQHVLQFHOO-matrix and cytokine/growth 
factor-receptor interactions, several connections via ILK, and increased transcript expression of EGF, 
3'*)ĮDQG,/.LQWKH<DQG<06&OLQHV [6].  
 
Protein was isolated from the hTERT-MSCs under basal conditions; the Y102 and Y202 lines 
expressed increased levels RIDFWLYDWHGGHSKRVSKRU\ODWHG ȕ-catenin and pERK at both passages by 
western blotting compared to Y101 and Y201 MSC lines (Fig. S1A). Y202 MSCs, which showed 
high endogenous pERK and ȕ-catenin levels, were selected for further analysis by treating with 
increasing concentrations of specific inhibitors of EGF receptor (EGFR), PDGF receptor (PDGFR) 
and ILK, which resulted in a dose-GHSHQGHQWUHGXFWLRQLQDFWLYHȕ-catenin protein levels (Fig. 1B). To 
examine the effects of RTK signalling inhibition on cell growth, hTERT-MSCs were treated for 24 
and 72 hours with EGFR and PDGFR inhibitors, before viable cell numbers were measured using the 
MTT assay. After 72 hours, all hTERT-MSC lines showed a significant reduction in cell number 
following treatment with a combination of both EGFR and PDGFR inhibitors, indicating reduced 
growth rate in response to RTK inhibition and providing evidence of autocrine RTK signalling. 
Furthermore, in all MSC lines, EGFR inhibition alone was sufficient to reduce significantly growth 
rate, whereas the inhibitory effects of PDGFR blockade were only significant in the presence of EGF 
(Fig. 1C). These initial findings provided circumstantial evidence that RTK (EGF predominantly) and 
,/.VLJQDOOLQJ ZHUHOLQNHGWRERWKȕ-catenin activation and hTERT-MSC proliferation.  
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To test for a direct association, human primary MSCs were used to ensure our observations were not 
an anomaly associated with the hTERT-MSCs. Primary MSCs were treated with EGF and PDGF 
alone or in combination with an ILK inhibitor (ILKi) and pERK and active ȕ-catenin expression was 
measured by western blotting after 24h. This confirmed that EGF and PDGF increased active ȕ-
catenin in primary MSCs; however inter-donor variation was notable with varying basal levels of 
active ȕ-catenin expression (examples shown in Fig. 1D with quantification in S1B, compare levels in 
control lane 1), in a manner similar to the variation observed across the hTERT-MSC lines. Inhibition 
of ILK did reduce EGF and PDGF-LQGXFHGDFWLYDWLRQRIȕ-catenin and notably, blockade of ILK 
increased basal ERK phosphorylation (e.g. Fig. 1D, compare band intensities in lanes 1 and 2, Control 
versus Control plus ILKi). 
 
Active ȕ-catenin levels are increased in primary MSCs in response to EGF and integrin 
signalling. 
We then focused on the time-course effects of EGF exposure on primary MSCs to delineate pERK/ȕ-
catenin pathway activation mechanisms. Protein was isolated from MSCs that had been treated with 
different FRQFHQWUDWLRQVRI(*)IRUPLQXWHVRUKRXUVDQGS(5.DQGDFWLYHȕ-catenin levels were 
measured by western blotting. An early transient increase in pERK expression was observed 
following 15 minutes exposure to all concentrations of EGF (1-100nM), which returned to control 
levels by 6 hours (Fig 2A)$FWLYHȕ-catenin levels were unchanged after 15 minutes of EGF 
WUHDWPHQWEXWDQLQFUHDVHLQDFWLYHȕ-catenin was observed at 6 hours (Fig. 2A). Flow cytometry was 
performed to determine expression of the EGFR and 3'*)5Į in four different human primary MSC 
donors; consisteQWO\KLJK H[SUHVVLRQRI3'*)5Įwas found. In contrast, the percentage of EGFR-
expressing cells varied considerably, from 45-77% positivity in the four MSC samples examined (Fig. 
2B). The MSCs analysed in Fig. 1D were recovered to determine EGFR/PDGFR expression by flow 
cytometry with variation again identified (Donor 1: 64% and 93%; Donor 2: 20% and 88% for EGFR 
and PDGFR respectively, Fig. S2A). Attempts were made to sort EGFR-positive MSCs but high 
EGFR levels were not maintained in culture and the populations reverted to variable EGFR 
expression (data not shown), which may be related to an autocrine EGF-EGFR negative feedback 
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response and ligand-induced internalisation of the EGFR [39]. These findings suggest that EGF-
LQGXFHGȕ-catenin activation occurs later than ERK phosphorylation, it is concentration-dependent and 
that responses may be determined by the EGFR expression profile within a heterogeneous MSC 
population.  
 
Considering the potential involvement of ILK in this signalling mechanism, cells were seeded onto 
plates coated with type I collagen, which is known to activate integrin signalling and drive ILK 
recruitment [40] and a dose-dependent increase in activation of ȕ-catenin was observed (Fig. S2B). 
This effect was examined further by treating primary MSCs with an RGD peptide that mimics integrin 
binding. By western blotting RGD treatmeQWLQFUHDVHGOHYHOVRIDFWLYHȕ-catenin, which was blocked 
by ILK inhibition, thus VXSSRUWLQJ DUROHIRUWKHUHJXODWLRQ RIDFWLYHȕ-catenin levels via ILK in 
primary human MSCs (Fig. 2B). 
 
EGF-induced activation of E-catenin may be unique to MSCs 
To determine if EGF-mediated activation of ȕ-catenin occurred in other stromal cells, a related cell 
type, human dermal fibroblasts (HDFs), was treated with EGF. An increase in pERK expression 
following EGF exposure for 15 minutes was observed with expression returning to control levels by 6 
hours, consistent with MSC responses (Fig S2C)1RWDEO\ DFWLYHȕ-catenin protein levels remained 
similar to untreated controls at both time points, indicating that EGF-LQGXFHGDFWLYDWLRQ RIȕ-catenin 
signalling does not occur in HDFs, and may be specific to MSCs (Fig. S2C).  
 
EGF treatment drives DFWLYHȕ-catenin nuclear translocation but does not induce TCF-mediated 
gene activation. 
)ROORZLQJ :QWVWLPXODWLRQ ȕ-catenin translocates to the nucleus to induce transcription of target 
genes by interacting with TCF/LEF transcription factors. AFWLYHȕ-catenin localisation in primary 
MSCs was examined following 6 hours of EGF treatment. Immunocytochemistry revealed nuclear 
staining followinJ WUHDWPHQWZLWKWKHSRVLWLYH FRQWURO :QWDDQGLQFUHDVHGQXFOHDUȕ-catenin staining 
was also observed following treatment with EGF, though to varying degrees in different MSC 
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samples (Fig. 3A, two MSC donors shown). QPCR was used to determine the effects of EGF 
WUHDWPHQWRQNQRZQȕ-catenin regulated genes; Axin2, c-Myc and Lef-1. Whilst Wnt3a stimulation 
increased expression of Axin2 and Lef-1, but not c-Myc, EGF had no effect on the expression of the 
three genes at any concentration tested (Fig. 3B).  
 
To investigate further, hTERT-MSCs (Y201) stably expressing a TCF-enhanced green fluorescent 
protein (EGFP) reporter [33] were used. Following treatment with Wnt3a, flow cytometric analysis 
revealed a significant increase in EGFP expression (96% positivity), indicating TCF activation. In 
contrast, negligible changes in EGFP expression (<0.5% positivity) were observed above controls at 
any EGF concentration (Fig. 3C, upper). These results were supported by fluorescent microscopic 
examination (Fig. 3C, lower). Finally, the mouse mesenchymal cell line, C3H10T1/2 was transiently 
transfected with a TCF/LEF-luciferase reporter and treated for 24 hours with EGF, LiCl (a GSK3ȕ 
inhibitor), NaCl (negative control) or Wnt3a. There was a significant increase in luciferase activity in 
cells treated with LiCl and Wnt3a compared to controls, whereas EGF treatment had no effect (Fig. 
3D). Taken together these results indicate that EGF induces nuclear WUDQVORFDWLRQRIȕ-catenin, but 
does not drive TCF-mediated gene expression. 
 
$FWLYDWLRQRIȕ-catenin by EGF does not influence Wnt-driven TCF-dependent gene expression. 
Until now, the effects of EGF and Wnt on ȕ-catenin activation have been studied independently, 
although the possibility exists, and is perhaps more likely, that MSCs in vivo are exposed to different 
concentrations of these factors simultaneously, working in concert. For example, EGF may be able to 
augment Wnt-induced transcriptional events via cooperative ȕ-catenin activation. To test this 
hypothesis, an efficient multi-factorial Design of Experiments (DoE) strategy was employed, where 
the hTERT-MSC TCF-EGFP reporter cells were exposed to different combinations and 
concentrations of EGF and Wnt3a in 9 parallel runs and TCF-mediated transcription (EGFP 
fluorescence) was determined by fluorimetry (Fig. 4A, S3A and S3B). These experiments 
conclusively demonstrated that EGF does not affect Wnt-induced transactivation. Contour plots of the 
effect of Wnt3a and EGF on EGFP fluorescence indicated that regardless of EGF concentration, Wnt 
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activation occurred in a dose-dependent manner (Fig. 4B). The fitted means of fluorescent response 
indicated similar trends, providing strong evidence that there was no interaction between Wnt3a and 
EGF (p = 0.382). The effect of EGF alone on the response was insignificant (p = 0.486), therefore 
differences between EGF concentrations were within error (Fig. 4C and 4D). Collectively, these 
findings demonstrate that activation and nuclear translocation of ȕ-catenin by EGF is independent of 
the Wnt-ȕ-catenin-TCF pathway. 
 
EGF controls MSC proliferation via ILK and ȕ-catenin activation  
Given the pronounced effects of EGFR inhibition on hTERT-MSC numbers, the role of the EGF-ILK-
ȕ-catenin pathway on proliferation in primary MSCs was analysed: viable MSC numbers were 
increased following 48 hours of EGF treatment, but this effect was negated by ILK inhibition (Fig. 
5A). AP-1 is a downstream target of EGF and pERK signalling and a known activator of cell 
proliferation. We demonstrated by western blot analysis that EGF induced early and transient 
expression of pc-Jun, which is part of the AP-1 complex (Fig. S4A and S4B). MSCs were treated with 
increasing concentrations of an AP-1 inhibitor in the presence and absence of EGF and again found 
that EGF significantly increased viable cell numbers of MSCs, and that this stimulatory effect was not 
affected by AP-1 inhibition (Fig. 5B) indicating that EGF-induced proliferation of MSCs was not 
mediated by the AP-1 complex.  
 
The role of the ȕ-catenin pathway in EGF-induced proliferation of primary MSCs was probed using 
IWR-1, a compound known to stabilise the APC/Axin/GSK-ȕGHVWUXFWLRQFRPSOH[WKURXJK
interaction with Axin2, thereby SUHYHQWLQJȕ-catenin nuclear translocation. Primary MSCs were 
treated for 48 hours with EGF alone or in combination with IWR-1, and proliferation measured by 
EdU incorporation and cell numbers by MTT assay. IWR-1 significantly reduced the proliferation of 
MSCs treated with EGF at 48hrs (Fig. 5C) and numbers of viable cells (Fig. S4C), demonstrating that 
ȕ-catenin activation is required for EGF-induced proliferation of primary human MSCs. 
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Classical (*)DQG(*)ȕ-catenin signalling pathways regulate the expression of distinct gene 
sets. 
An experimental strategy was devised to determine the different gene sets that were regulated by 
³classical´ (*)signalling and the EGF/ȕ-catenin signalling pathway (Fig. S5A). Primary human 
MSCs were treated (in triplicate) with EGF alone or EGF with IWR-1 for 24h and changes in gene 
expression were determined by RNA-Seq analysis, compared to untreated controls. By examining 
statistical differences between the treatment groups, classical EGF gene targets, those showing 
significant (P<0.05) differences in [control versus EGF] and [control versus EGF + IWR1] but not 
[EGF versus EGF + IWR1] were identifiable; likewise, EGF/ȕ-catenin gene targets were identified as 
showing significant differences between [control versus EGF] and [EGF versus EGF + IWR1] but not 
[control versus EGF + IWR1]. These comparisons generated lists of 879 classical EGF-regulated 
JHQHVDQG(*)ȕ-catenin-regulated genes that were subjected to Gene Set Enrichment Analysis 
(GSEA: Hallmarks and Gene Ontology: Biological Processes). Different, significantly enriched 
Hallmarks and Biological Processes (BP) were identified for the classical EG)DQG(*)ȕ-catenin 
pathways (Table S1). Independent analysis of upregulated and downregulated genes showed that the 
most significantly downregulated classical EGF-regulated pathways were associated with cell 
proliferation including the Hallmarks E2F Targets; G2M Checkpoint, Mitotic Spindle and GO Terms 
Cell Cycle, Cell Cycle Process; Mitotic Cell Cycle; Cell Division (Fig. 6A and Fig. S5B-D). 
Upregulated classical EGF-regulated pathways were associated largely with cell defence responses, 
tissue development and differentiation (Fig. 6A). In contrast, Hallmarks and Biological Processes that 
ZHUHVLJQLILFDQWO\ LQIOXHQFHG E\WKH(*)ȕ-catenin pathway included immune responses, KRas 
signalling and stress responses, amongst others (Fig. 6B).  
 
A scatter plot was used to display the data based on differences across the Control/EGF/EGF + IWR-1 
treatment groups (Fig. 7A). It should be noted that these separations were based on a significance 
threshold of P<0.05, so some false positive and negatives may be included. Visualising the data in this 
manner clearly identified at least four differentially regulated sets of genes; the classical EGF-
regulated genes are represented as dark blue spots (gene set 1, lower right quadrant, Fig. 7A) and the 
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(*)ȕ-catenin-regulated genes as yellow spots (gene set 2, upper right quadrant, Fig. 7A).  There 
were also gene sets whose expression appeared WREHLQIOXHQFHG E\WKH(*)ȕ-catenin pathway; 
classical-regulated genes that weUHHLWKHUIXUWKHULQFUHDVHGRUGHFUHDVHGE\DQDFWLYH(*)ȕ-catenin 
pathway (gene set 3, light blue spots, upper right quadrant, Fig. 7A) and classical EGF-regulated 
genes whose expression was GHSHQGHQWRQDQDFWLYH(*)ȕ-catenin pathway (gene set 4, purple spots, 
upper left quadrant, Fig. 7A). We have proposed a model as a potential mechanism by which this 
regulatory control may occur (Fig. 7B) with an updated interpretation of EGF signalling pathways in 
MSCs (Fig. 7C). 
 
 
Discussion 
By attempting to understand the roles of growth factor and integrin signalling in human MSCs, we 
have identified a Wnt ligand-LQGHSHQGHQW PHFKDQLVPRIȕ-catenin activation, mediated by EGF. 
E-catenin activation via EGF/EGFR induction has been demonstrated in a number of studies using 
cancer cells. For example, the internalisation of E-cadherin following EGF treatment results in the 
GLVVRFLDWLRQ RIȕ-catenin from the cadherin complex, nuclear translocation and activation of TCF/LEF 
gene targets including c-Myc and cyclin D1 [41, 42]. This may also be aided by the co-binding of 
embryonic pyruvate kinase M2 (PKM2), which is present at high levels in multiple human cancer 
lines [20]. It is important to note that cancer cells frequently over-express EGFR with defective 
negative feedback responses [39]; characteristics that are not a feature of normal human cells. Related 
reports using human urothelial cells have also pointed to a relationship between EGF and Wnt 
signalling, albeit in this case operating together in a positive feedback mechanism to control 
proliferation and again via TCF activation [43]. The data presented here demonstrate a role for EGF 
VLJQDOOLQJ LQȕ-catenin activation and nuclear translocation in normal human MSCs. However, this 
mechanism of signalling does not appear to be a feature of all stromal cells as EGF treatment of HDFs 
GLGQRWGULYHDFFXPXODWLRQRIDFWLYHȕ-catenin. Our data implicate the involvement of ILK in EGF-
LQGXFHGDFWLYHȕ-FDWHQLQDFFXPXODWLRQ LQSULPDU\06&V7KLVDOWHUQDWLYHURXWHRIȕ-catenin activation 
may be due to the interaction of RTK adaptor proteins on the intracellular face of the plasma 
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membrane, leading to activation of the ILK kinase domain and subsequent inhibition of GSK-ȕ[19]. 
Unlike previous work in other cell types, we did not observe increased TCF-driven gene transcription 
following EGF-PHGLDWHGȕ-catenin nuclear translocation in MSCs. Furthermore, we clearly 
demonstrated by DoE that EGF could not influence Wnt-induced TCF reporter activity. Indeed, 
maximum reporter levels were achieved with no/low EGF and high Wnt concentrations, providing 
strong evidence that the EGF/ ȕ-catenin signalling pathway in MSCs does not act via TCF, but 
operates through distinct mechanism to regulate the expression of different target gene sets. 
Bioinformatics analysis of the RNA-Seq data identified at least four distinct gene sets that were 
exclusively regulated either by classical (*)RU(*)ȕ-catenin pathways, as well genes that were co-
regulated by both pathways, demonstrating the complexity of this signal transduction mechanism. 
These analyses also highlighted a potential mechanism through which EGF controls MSC 
proliferation. Blockade RIȕ-catenin activation prevented EGF-induced proliferation by enhancing the 
inhibitory effects of classical EGF signalling on cell cycle-related pathways. 
 
We observed inter-donor variation as well as intra-donor variation (using the hTERT-MSC clonal 
lines), which may be linked to varying basal levels of endogenous EGF and/or E-catenin signalling 
activity across MSC populations and reflect authentic biological function. Indeed this biological 
variation may have obscured the discovery of this signalling pathway in MSCs. We have used 
primary MSCs from 10 donors, plus four MSC clonal lines, throughout the course of this work in an 
attempt to aid accurate interpretation of the data and primary MSCs were used at similar passages (up 
to a maximum of passage 5) to help minimise variations due to in vitro culture conditions. The 
importance of these findings extends beyond a fundamental understanding of MSC biology. Many 
previous studies, using both in vitro and in vivo PHWKRGVKDYHDVVHVVHGȕ-catenin signalling in MSCs 
and highlighted its importance in bone formation3HUWXUEDWLRQVLQȕ-catenin signalling have resulted 
in greatly reduced bone formation [44], loss of osteogenic tissues and altered skeletal development 
[45]GHPRQVWUDWLQJDFULWLFDOUROHIRUȕ-catenin in these processes. Along with numerous other studies 
[14, 15, 46, 47], WKLVSUHYLRXVO\ SXEOLVKHG ZRUNFRQVLGHUHGWKHUHJXODWLRQ RIȕ-catenin activity in the 
context of canonical Wnt signalling and there is widespread interest in using modulators of Wnt/ȕ-
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catenin to treat bone disease [48].  The findings presented here clearly demonstrate an alternative, 
Wnt-LQGHSHQGHQW PHFKDQLVPIRUȕ-FDWHQLQDFWLYDWLRQ LQKXPDQ06&V7KHUHDUHUHSRUWVWKDWȕ-
catenin can induce gene expression in a TCF/LEF-independent manner, through E-box element 
binding [49] and via vitamin D response elements [50, 51], and similar mechanisms may be acting in 
MSC cultures. This study highlights the need for more detailed analysis of both classical and 
DOWHUQDWLYHURXWHVIRUȕ-catenin activation to ensure that the integrated signalling mechanisms 
controlling MSC function are fully uncovered. These endeavours will also impact the development of 
new therapies for skeletal disorders, particularly those related to the use of Wnt signalling mimetics. 
 
 
Acknowledgements 
This work was supported by the Arthritis Research UK Tissue Engineering Centre (19429), and 
Arthritis Research UK grant (20575), the Biotechnology and Biological Sciences Research Council 
and Medical Research Council. We are very grateful to staff and patients of Clifton Park Hospital for 
samples. Microscopy and flow cytometry was undertaken in the Imaging and Cytometry Lab, and 
RNA-Seq, bioinformatics analysis and QPCR through the Genomics and Bioinformatics Lab within 
the Bioscience Technology Facility. 
 
 
 
 
 
 
 
 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
References 
[1] A. Carstairs, P. Genever, Stem cell treatment for musculoskeletal disease, Curr Opin Pharmacol 16 
(2014) 1-6. 
[2] C. Bluguermann, L. Wu, F. Petrigliano, D. McAllister, S. Miriuka, D.A. Evseenko, Novel aspects 
of parenchymal±mesenchymal interactions: from cell types to molecules and beyond, Cell 
Biochemistry and Function 31(4) (2013) 271-280. 
[3] M.F. Pittenger, A.M. Mackay, S.C. Beck, R.K. Jaiswal, R. Douglas, J.D. Mosca, M.A. Moorman, 
D.W. Simonetti, S. Craig, D.R. Marshak, Multilineage potential of adult human mesenchymal stem 
cells, Science 284(5411) (1999) 143-7. 
[4] E. Jones, D. McGonagle, Human bone marrow mesenchymal stem cells in vivo, Rheumatology 
(Oxford) 47(2) (2008) 126-31. 
[5] M. Pevsner-Fischer, S. Levin, D. Zipori, The origins of mesenchymal stromal cell heterogeneity, 
Stem Cell Rev 7(3) (2011) 560-8. 
[6] S. James, J. Fox, F. Afsari, J. Lee, S. Clough, C. Knight, J. Ashmore, P. Ashton, O. Preham, M. 
Hoogduijn, A. Ponzoni Rde, Y. Hancock, M. Coles, P. Genever, Multiparameter Analysis of Human 
Bone Marrow Stromal Cells Identifies Distinct Immunomodulatory and Differentiation-Competent 
Subtypes, Stem Cell Reports 4(6) (2015) 1004-15. 
>@%5XELQIHOG ,$OEHUW(3RUILUL &)LRO 60XQHPLWVX 33RODNLV%LQGLQJ RI*6.ȕWRWKH
APC-ȕ-catenin complex and regulation of complex assembly, Science 272(5264) (1996) 1023-6. 
[8] E. Brunner, O. Peter, L. Schweizer, K. Basler, pangolin encodes a Lef-1 homologue that acts 
downstream of Armadillo to transduce the Wingless signal in Drosophila, Nature 385(6619) (1997) 
829-33. 
[9] M. van de Wetering, R. Cavallo, D. Dooijes, M. van Beest, J. van Es, J. Loureiro, A. Ypma, D. 
Hursh, T. Jones, A. Bejsovec, M. Peifer, M. Mortin, H. Clevers, Armadillo coactivates transcription 
driven by the product of the Drosophila segment polarity gene dTCF, Cell 88(6) (1997) 789-99. 
[10] Y. Gong, R.B. Slee, N. Fukai, G. Rawadi, S. Roman-Roman, A.M. Reginato, H. Wang, T. 
Cundy, F.H. Glorieux, D. Lev, M. Zacharin, K. Oexle, J. Marcelino, W. Suwairi, S. Heeger, G. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
Sabatakos, S. Apte, W.N. Adkins, J. Allgrove, M. Arslan-Kirchner, J.A. Batch, P. Beighton, G.C. 
Black, R.G. Boles, L.M. Boon, C. Borrone, H.G. Brunner, G.F. Carle, B. Dallapiccola, A. De Paepe, 
B. Floege, M.L. Halfhide, B. Hall, R.C. Hennekam, T. Hirose, A. Jans, H. Juppner, C.A. Kim, K. 
Keppler-Noreuil, A. Kohlschuetter, D. LaCombe, M. Lambert, E. Lemyre, T. Letteboer, L. Peltonen, 
R.S. Ramesar, M. Romanengo, H. Somer, E. Steichen-Gersdorf, B. Steinmann, B. Sullivan, A. 
Superti-Furga, W. Swoboda, M.J. van den Boogaard, W. Van Hul, M. Vikkula, M. Votruba, B. Zabel, 
T. Garcia, R. Baron, B.R. Olsen, M.L. Warman, G. Osteoporosis-Pseudoglioma Syndrome 
Collaborative, LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development, Cell 
107(4) (2001) 513-23. 
[11] G.M. Boland, G. Perkins, D.J. Hall, R.S. Tuan, Wnt 3a promotes proliferation and suppresses 
osteogenic differentiation of adult human mesenchymal stem cells, J Cell Biochem 93(6) (2004) 
1210-30. 
[12] J. De Boer, H.J. Wang, C. Van Blitterswijk, Effects of Wnt signaling on proliferation and 
differentiation of human mesenchymal stem cells, Tissue Eng 10(3-4) (2004) 393-401. 
[13] S.L. Etheridge, G.J. Spencer, D.J. Heath, P.G. Genever, Expression profiling and functional 
analysis of wnt signaling mechanisms in mesenchymal stem cells, Stem Cells 22(5) (2004) 849-60. 
[14] D.A. Cook, S.W. Fellgett, M.E. Pownall, P.J. O'Shea, P.G. Genever, Wnt-dependent osteogenic 
commitment of bone marrow stromal cells using a novel GSK3beta inhibitor, Stem Cell Res 12(2) 
(2014) 415-27. 
[15] G. Bain, T. Muller, X. Wang, J. Papkoff, Activated beta-catenin induces osteoblast 
differentiation of C3H10T1/2 cells and participates in BMP2 mediated signal transduction, Biochem 
Biophys Res Commun 301(1) (2003) 84-91. 
[16] G. Rawadi, B. Vayssiere, F. Dunn, R. Baron, S. Roman-Roman, BMP-2 controls alkaline 
phosphatase expression and osteoblast mineralization by a Wnt autocrine loop, J Bone Miner Res 
18(10) (2003) 1842-53. 
[17] S. Dedhar, B. Williams, G. Hannigan, Integrin-linked kinase (ILK): a regulator of integrin and 
growth-factor signalling, Trends in Cell Biology 9(8) (1999) 319-323. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
[18] M. Delcommenne, C. Tan, V. Gray, L. Rue, J. Woodgett, S. Dedhar, Phosphoinositide-3-OH 
kinase-dependent regulation of glycogen synthase kinase 3 and protein kinase B/AKT by the integrin-
linked kinase, Proceedings of the National Academy of Sciences of the United States of America 
95(19) (1998) 11211-11216. 
[19] S. Naska, K.J. Park, G.E. Hannigan, S. Dedhar, F.D. Miller, D.R. Kaplan, An essential role for 
the integrin-linked kinase-glycogen synthase kinase-3 beta pathway during dendrite initiation and 
growth, J Neurosci 26(51) (2006) 13344-56. 
>@:<DQJ<;LD +-L<=KHQJ-/LDQJ:+XDQJ;*DR1XFOHDU3.0UHJXODWHVȕ-
catenin transactivation upon EGFR activation, Nature 478(7375) (2011) 118-122. 
[21] P. Krejci, A. Aklian, M. Kaucka, E. Sevcikova, J. Prochazkova, J.K. Masek, P. Mikolka, T. 
Pospisilova, T. Spoustova, M. Weis, W.A. Paznekas, J.H. Wolf, J.S. Gutkind, W.R. Wilcox, A. 
Kozubik, E.W. Jabs, V. Bryja, L. Salazar, I. Vesela, L. Balek, Receptor tyrosine kinases activate 
canonical WNT/beta-catenin signaling via MAP kinase/LRP6 pathway and direct beta-catenin 
phosphorylation, PLoS One 7(4) (2012) e35826. 
[22] X. Zhang, J. Zhu, Y. Li, T. Lin, V.A. Siclari, A. Chandra, E.M. Candela, E. Koyama, M. 
Enomoto-Iwamoto, L. Qin, Epidermal growth factor receptor (EGFR) signaling regulates epiphyseal 
cartilage development through beta-catenin-dependent and -independent pathways, J Biol Chem 
288(45) (2013) 32229-40. 
[23] M.B. Greenblatt, D.Y. Shin, H. Oh, K.-Y. Lee, B. Zhai, S.P. Gygi, S. Lotinun, R. Baron, D. Liu, 
B. Su, L.H. Glimcher, J.-+6KLP 0(..PHGLDWHVDQDOWHUQDWLYHȕ-catenin pathway that promotes 
bone formation, Proceedings of the National Academy of Sciences 113(9) (2016) E1226-E1235. 
[24] M. Sibilia, B. Wagner, A. Hoebertz, C. Elliott, S. Marino, W. Jochum, E.F. Wagner, Mice 
humanised for the EGF receptor display hypomorphic phenotypes in skin, bone and heart, 
Development 130(19) (2003) 4515-4525. 
[25] M.C. Fisher, G.M. Clinton, N.J. Maihle, C.N. Dealy, Requirement for ErbB2/ErbB signaling in 
developing cartilage and bone, Development, Growth & Differentiation 49(6) (2007) 503-513. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
[26] X. Zhang, V.A. Siclari, S. Lan, J. Zhu, E. Koyama, H.L. Dupuis, M. EnomotoǦ Iwamoto, F. 
Beier, L. Qin, The Critical Role of the Epidermal Growth Factor Receptor in Endochondral 
Ossification, Journal of Bone and Mineral Research 26(11) (2011) 2622-2633. 
[27] X. Zhang, J. Tamasi, X. Lu, J. Zhu, H. Chen, X. Tian, T.C. Lee, D.W. Threadgill, B.E. Kream, 
Y. Kang, N.C. Partridge, L. Qin, Epidermal growth factor receptor plays an anabolic role in bone 
metabolism in vivo, Journal of Bone and Mineral Research 26(5) (2011) 1022-1034. 
[28] M. Krampera, A. Pasini, A. Rigo, M.T. Scupoli, C. Tecchio, G. Malpeli, A. Scarpa, F. Dazzi, G. 
Pizzolo, F. Vinante, HB-EGF/HER-1 signaling in bone marrow mesenchymal stem cells: inducing 
cell expansion and reversibly preventing multilineage differentiation, Blood 106(1) (2005) 59-66. 
[29] K. Tamama, V.H. Fan, L.G. Griffith, H.C. Blair, A. Wells, Epidermal growth factor as a 
candidate for ex vivo expansion of bone marrow-derived mesenchymal stem cells, Stem Cells 24(3) 
(2006) 686-95. 
[30] S. Yu, Q. Geng, J. Ma, F. Sun, Y. Yu, Q. Pan, A. Hong, Heparin-binding EGF-like growth factor 
and miR-1192 exert opposite effect on Runx2-induced osteogenic differentiation, Cell Death Dis 4 
(2013) e868. 
[31] X. Liu, J. Qin, Q. Luo, Y. Bi, G. Zhu, W. Jiang, S.H. Kim, M. Li, Y. Su, G. Nan, J. Cui, W. 
Zhang, R. Li, X. Chen, Y. Kong, J. Zhang, J. Wang, M.R. Rogers, H. Zhang, W. Shui, C. Zhao, N. 
Wang, X. Liang, N. Wu, Y. He, H.H. Luu, R.C. Haydon, L.L. Shi, T. Li, T.C. He, M. Li, Cross-talk 
between EGF and BMP9 signalling pathways regulates the osteogenic differentiation of mesenchymal 
stem cells, J Cell Mol Med 17(9) (2013) 1160-72. 
[32] K. Boonanantanasarn, H.L. Lee, K. Baek, K.M. Woo, H.M. Ryoo, J.H. Baek, G.S. Kim, EGF 
,QKLELWV :QWȕǦ CateninǦ ,QGXFHG2VWHREODVW'LIIHUHQWLDWLRQ E\3URPRWLQJȕǦ Catenin Degradation, 
Journal of Cellular Biochemistry 116(12) (2015) 2849-2857. 
[33] F. Saleh, A. Carstairs, S.L. Etheridge, P. Genever, Real-Time Analysis of Endogenous Wnt 
Signalling in 3D Mesenchymal Stromal Cells, Stem Cells Int 2016 (2016) 7132529. 
[34] M. Martin, Cutadapt removes adapter sequences from high-throughput sequencing reads, 
EMBnet.journal 17(1) (2011) 10-12. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
[35] D. Kim, B. Langmead, S.L. Salzberg, HISAT: a fast spliced aligner with low memory 
requirements, Nature Methods 12 (2015) 357. 
[36] C. Trapnell, A. Roberts, L. Goff, G. Pertea, D. Kim, D.R. Kelley, H. Pimentel, S.L. Salzberg, J.L. 
Rinn, L. Pachter, Differential gene and transcript expression analysis of RNA-seq experiments with 
TopHat and Cufflinks, Nature Protocols 7(3) (2012) 562-578. 
[37] R Core Team, R: A language and environment for statistical computing. R Foundation for 
Statistical Computing, Vienna, Austria, 2016. 
[38] A. Subramanian, P. Tamayo, V.K. Mootha, S. Mukherjee, B.L. Ebert, M.A. Gillette, A. 
Paulovich, S.L. Pomeroy, T.R. Golub, E.S. Lander, J.P. Mesirov, Gene set enrichment analysis: A 
knowledge-based approach for interpreting genome-wide expression profiles, Proceedings of the 
National Academy of Sciences 102(43) (2005) 15545-15550. 
[39] R. Avraham, Y. Yarden, Feedback regulation of EGFR signalling: decision making by early and 
delayed loops, Nat Rev Mol Cell Biol 12(2) (2011) 104-17. 
[40] A. Leyme, K. Bourd-Boittin, D. Bonnier, A. Falconer, Y. Arlot-Bonnemains, N. Theret, 
Identification of ILK as a new partner of the ADAM12 disintegrin and metalloprotease in cell 
adhesion and survival, Mol Biol Cell 23(17) (2012) 3461-72. 
[41] Z. Lu, S. Ghosh, Z. Wang, T. Hunter, Downregulation of caveolin-1 function by EGF leads to the 
loss of E-FDGKHULQLQFUHDVHGWUDQVFULSWLRQDO DFWLYLW\RIȕ-catenin, and enhanced tumor cell invasion, 
Cancer Cell 4(6) (2003) 499-515. 
[42] C.H. Lee, H.W. Hung, P.H. Hung, Y.S. Shieh, Epidermal growth factor receptor regulates beta-
catenin location, stability, and transcriptional activity in oral cancer, Mol Cancer 9 (2010) 64. 
[43] N.T. Georgopoulos, L.A. Kirkwood, J. Southgate, A novel bidirectional positive-feedback loop 
between Wnt-ȕ-catenin and EGFR-ERK plays a role in context-specific modulation of epithelial 
tissue regeneration, J Cell Sci 127(Pt 13) (2014) 2967-82. 
[44] J. Chen, F. Long, Beta-catenin promotes bone formation and suppresses bone resorption in 
postnatal growing mice, J Bone Miner Res 28(5) (2013) 1160-9. 
>@73+LOO '6SlWHU007DNHWR:%LUFKPHLHU &DQRQLFDO:QWȕ-catenin signaling prevents 
osteoblasts from differentiating into chondrocytes, Developmental cell 8(5) (2005) 727-738. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
[46] S.L. Holmen, C.R. Zylstra, A. Mukherjee, R.E. Sigler, M.C. Faugere, M.L. Bouxsein, L. Deng, 
7/&OHPHQV%2:LOOLDPV (VVHQWLDOUROHRIȕ-catenin in postnatal bone acquisition, J Biol Chem 
280(22) (2005) 21162-8. 
[47] N.H. Kulkarni, J.E. Onyia, Q. Zeng, X. Tian, M. Liu, D.L. Halladay, C.A. Frolik, T. Engler, T. 
Wei, A. Kriauciunas, T.J. Martin, M. Sato, H.U. Bryant, Y.L. Ma, Orally bioavailable GSK-
3alpha/beta dual inhibitor increases markers of cellular differentiation in vitro and bone mass in vivo, 
J Bone Miner Res 21(6) (2006) 910-20. 
[48] U. Krause, S. Harris, A. Green, J. Ylostalo, S. Zeitouni, N. Lee, C.A. Gregory, Pharmaceutical 
modulation of canonical Wnt signaling in multipotent stromal cells for improved osteoinductive 
therapy, Proceedings of the National Academy of Sciences 107(9) (2010) 4147-4152. 
>@&+.LP+1HLVZHQGHU(-%DLN:&;LRQJ /0HLȕ-catenin interacts with MyoD and 
regulates its transcription activity, Mol Cell Biol 28(9) (2008) 2941-51. 
[50] H.G. Palmer, J.M. Gonzalez-Sancho, J. Espada, M.T. Berciano, I. Puig, J. Baulida, M. 
Quintanilla, A. Cano, A.G. de Herreros, M. Lafarga, . Munoz, Vitamin D(3) promotes the 
differentiation of colon carcinoma cells by the induction of E-FDGKHULQDQGWKHLQKLELWLRQ RIȕ-catenin 
signaling, J Cell Biol 154(2) (2001) 369-87. 
[51] S. Shah, N. Islam, S. Dakshanamurthy, I. Rizvi, M. Rao, R. Herrell, G. Zinser, M. Valrance, A. 
Aranda, D. Moras, A. Norman, J. Welsh, S.W. Byers, The molecular basis of vitamin D receptor and 
beta-catenin crossregulation, Molecular Cell 21(6) (2006) 799-809. 
 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
Figure titles and legends 
)LJXUH57.,/.DQGȕ-catenin signalling are interrelated in human MSCs. (A) Schematic of 
EGF and Wnt/E-catenin signal transduction mechanisms. (B) Analysis of the effects of ILK, EGFR 
DQG3'*)5VLJQDOOLQJ LQKLELWLRQ RQDFWLYHȕ-catenin levels in Y202 hTERT MSCs by western 
blotting. (C) MTT assay of viable cell numbers of hTERT MSCs following 24 and 72 hours of RTK 
signalling inhibition, graphs show mean absorbance ± SEM (n = 6), * = p<0.05, ** = p<0.005, *** = 
p<0.001. (D:HVWHUQEORWDQDO\VLVRIDFWLYHȕ-catenin and pERK levels in primary MSCs following 
EGF and PDGF exposure in the presence and absence of ILK inhibition (ILKi), donors K102 and K96 
shown. Densitometric analysis of band intensity normalised to GAPDH expression is shown in Fig. 
S1B. See also Figure S1. 
 
FiguUH$FWLYHȕ-catenin levels are increased in primary MSCs in response to EGF and 
integrin signalling. $:HVWHUQEORWDQDO\VLVRIDFWLYHȕ-catenin and pERK expression in primary 
MSCs in response to treatment with different concentrations of EGF for 15 minutes and 6 hours. 
Below, densitometric analysis of band intensity normalised to GAPDH expression, mean intensity ± 
SEM for two different primary MSC donors (K135 and K139) (B) Flow cytometric analysis of basal 
EGFR and PDGFR expression in 4 primary MSC donors (K85, K148, K149 and K153). (C) Western 
EORWDQDO\VLVRIDFWLYHȕ-catenin and pERK expression in MSCs following treatment with an RGD 
peptide in the presence and absence of ILK inhibition (ILKi), example blot shown in left panel, graph 
in right panel VKRZVGHQVLWRPHWULF DQDO\VLVRIȕ-catenin mean intensity ± SEM for two different 
primary MSC donors (K102 and K96). See also Figure S2. 
 
)LJXUH(*)WUHDWPHQWGULYHVDFWLYHȕ-catenin nuclear translocation but does not induce TCF-
mediated gene activation. $$QDO\VLVRIDFWLYHȕ-catenin nuclear localisation following EGF (1-
100nM) treatment in two primary MSC donors (K135 and K139) by immunofluorescence detection 
UHG DFWLYHȕ-catenin; blue = DAPI nuclear stain; IgG = antibody control; Basal = untreated control; 
Wnt3a = positive control%43&5DQDO\VLVRIȕ-catenin responsive genes Axin2, c-Myc and LEF-1 
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in primary MSCs after EGF or Wnt3a treatment. Values shown are mean expression ± SEM (n = 2, 
K135 and K139), normalised to GAPDH expression and relative to expression in untreated control 
samples. (C) Flow cytometric (upper panel) and immunofluorescent (lower panel) analysis of hTERT 
MSCs stably expressing a TCF-EGFP reporter following treatment with Wnt3a or EGF (1-100nM). 
(D) TOPflash Wnt reporter (M50) assay of mouse mesenchymal cells (C3H10T1/2 cells) treated with 
the Wnt signalling activator, (LiCl with NaCl negative control, upper panel) or with Wnt3a (lower 
panel) and EGF values shown are mean fold change ± SEM (n = 6), normalised to control samples, 
*** = p< 0.001). M51 = negative control. 
 
)LJXUH$FWLYDWLRQRIȕ-catenin by EGF is independent of Wnt signalling and does not drive 
TCF reporter expression. (A) Colour-coded schematic showing the 9-run experimental set-up with 
different combinations and concentration of EGF (0-100nM) and Wnt3A (0-300ng/ml). (B) Contour 
plot showing the effects of Wnt3a and EGF on the TCF-EGFP response. Dark green areas represent 
higher response. (C)  Fitted predictive model of TCF reporter fluorescent response. Similar trends 
indicate insignificant effect of EGF on Wnt activation. (D) Bar graph in standard order of factorial 
design showing combined effects of Wnt and EGF in TCF reporter activity (fluorescence). See also 
Figure S3. 
 
Figure 5. (*)FRQWUROV06&SUROLIHUDWLRQYLD,/.DQGȕ-catenin activation. (A) MTT assay of 
viable cell numbers in two primary MSC donors following 24 and 48 hours treatment with EGF and 
ILKi, graphs show mean absorbance ± SEM (n = 6), * = p<0.05. (B) MTT assay of viable cell 
numbers in two primary MSC donors following 120 hours treatment with EGF and increasing 
concentrations of an inhibitor of the AP-1 complex (AP-1i, concentrations = 17nM, 34nM and 68nM), 
graphs show mean absorbance ± SEM (n = 6), * = p<0.05, **<0.01 ***<0.001. (C) EdU proliferation 
assay in two primary MSC donors following 48 hours treatment with EGF, IWR-1 and Wnt3A, 
graphs show mean percentage EdU positive cells ± SEM (n = 23), * = p<0.05, **<0.01 ***<0.001, 
****<0.0001. Donor 1 = K168, Donor 2 = K185. See also Figure S4. 
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Figure 6. Classical EGF and EGF/E-catenin signalling pathways control the expression of 
distinct gene sets. (A) GSEA and GO Term bioinformatics analysis showing Hallmarks and 
Biological Processes significantly downregulated and upregulated in response to classical EGF 
signalling. (B) GSEA and GO Term bioinformatics analysis showing Hallmarks and Biological 
Processes significantly downregulated and upregulated in response to EGF/E-catenin signalling. See 
also Figure S5 and Table S1. 
 
Figure 7. EGF regulates at least four distinct gene sets. (A) Scatterplot of differentially expressed 
genes following EGF exposure for 24h, with or without IWR-1. EGF can signal via classical (1, dark 
blue) and EGF/E-catenin (2, yellow) pathways. The expression of other EGF targets can be up- or 
down-regulated (3, light blue) or abolished (4, purple) by activated E-catenin. (B) Schematic to 
summarise the different EGF-regulated gene sets. (C) Proposed model of EGF signalling pathways in 
MSCs. 
 
Figure S1. Basal RTK signalling levels vary in immortalised human MSCs  and are influenced 
by ILK signalling. $:HVWHUQEORWDQDO\VLVRIEDVDOH[SUHVVLRQRIS(5.DQGDFWLYHȕ-catenin in 
different hTERT MSC clonal lines at two different passages (Expt. 1 and 2), densitometry is shown in 
the graphs, mean intensity ± SEM for two different passages (n = 2), normalised to GAPDH 
expression and made relative to expression in Y101 hTERT MSCs. (B) Densitometric analysis of 
band intensity normalised to GAPDH expression for Western Blots shown in Fig. 1D (Donors K102 
and K96). 
 
Figure 6$FWLYHȕ-catenin expression in response to EGF and integrin signalling in human 
primary cells. (A) Flow cytometric analysis of basal EGFR and PDGFR expression in the 2 primary 
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MSC donors (K102 and K96) examined by western blotting in Fig. 1D. (B) Western blot analysis of 
DFWLYHȕ-catenin expression in primary MSCs seeded onto plates coated with type I collagen and 
cultured for 18 hours. (Representative blot is shown on the left, and densitometric analysis is shown in 
the graph as mean band intensity ± SEM (n = 2, donors K102 and K96), normalised to expression of 
GAPDH). (C:HVWHUQEORWDQDO\VLVRIDFWLYHȕ-catenin expression in HDFs in response to treatment 
with EGF or Wnt3a as the positive control, a representative blot is shown on the left. Graphs show 
densitometric analysis of mean band intensity ± SEM (n = 2), normalised to expression of GAPDH.  
 
Figure S3. Diagram outlining the overall DoE process. (A) A DoE is designed like most other 
experiments by first identifying the question to be answered, then the factors to be tested (inputs) are 
determined (EGF and Wnt3a). The output measured is the response to a change in the inputs (TCF-
EGFP reporter activity) and the high and low settings (levels) of the inputs are set. More levels can be 
included in DoEs, but for screening purposes, 2 ± 3 is sufficient. Once set, a full factorial experiment 
is designed (see S3B). Data collection and analysis follows, where the experiment is carried out and 
trends are plotted using linear models. Initially, few midpoints are included in the experimental design 
in order to keep the number of experiments low. (B)  Factor combinations are randomised in a DoE, 
helping to minimise effects of unaccounted for variables, such as systemic error in seeding density. 
One set of 9 runs is referred to as a block, where each block represents one replicate.  
 
Figure S4. EGF treatment drives transient early expression of phospho c-Jun and proliferation 
LQSULPDU\ 06&VZKLFKLVUHGXFHGE\EORFNDGHȕ-catenin nuclear translocation with IWR-1. 
(A) Western blot analysis of phospho c-Jun (pc-Jun) expression in 2 primary MSC donors (K135 and 
K139) treated with EGF for 15 minutes or 6 hours. (B) Densitometric analysis of Westerns blots 
shown above (15 minutes), graphs show band intensity normalised to expression of GAPDH. (C) 
MTT assay of viable cell numbers in two primary MSC donors (K168 and K185) following 48 ± 120 
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hours treatment with EGF and increasing concentrations of IWR-1, graphs show mean absorbance ± 
SEM (n = 6), **<0.01 ***<0.001. 
 
Figure S5. Identifying FODVVLFDO(*)DQG(*)ȕ-catenin signalling pathways in MSCs. (A) 
Experimental strategy to determine Classical EGF- DQG(*)ȕ-catenin-regulated gene sets. (B, C, D) 
Classical EGF signalling downregulates genes associated with the cell cycle in MSCs. Graphs show 
effects of classical EGF activation on individual genes associated with the most significantly 
downregulated Hallmarks; E2F Targets (B); G2M Checkpoint (C) and Mitotic Spindle (D). 
 
7DEOH6&ODVVLFDO(*)DQG(*)ȕ-catenin signalling pathways significantly enrich different 
gene sets in MSCs.  Lists of most significantly differentially enriched Hallmarks for classical EGF 
DQG(*)ȕ-catenin signalling pathways (upper panels). Lists of most significantly differentially 
HQULFKHG%LRORJLFDO 3URFHVVHVIRUFODVVLFDO(*)DQG(*)ȕ-catenin signalling pathways (lower 
panels). 
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Highlights 
x Epidermal growth factor (EGF) controls mesenchymal stem cell (MSC) proliferation. 
x EGF signals through E-catenin in MSCs but not in related fibroblastic cells. 
x Classical EGF and EGF/E-catenin cooperatively regulate distinct gene sets in MSCs. 
x EGF/E-catenin enables MSC proliferation by alleviating cell cycle suppression. 
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